| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bile Acids and Salts | 10 | 2019 | 91 | 3.49 | Why? |
| Receptors, G-Protein-Coupled | 7 | 2019 | 309 | 2.96 | Why? |
| Receptors, Cytoplasmic and Nuclear | 3 | 2019 | 67 | 1.45 | Why? |
| Cholestasis | 5 | 2018 | 114 | 1.28 | Why? |
| Cholestasis, Intrahepatic | 3 | 2019 | 28 | 1.13 | Why? |
| Bile Ducts | 3 | 2018 | 84 | 0.91 | Why? |
| Severe Combined Immunodeficiency | 1 | 2021 | 107 | 0.81 | Why? |
| Bile Duct Diseases | 1 | 2018 | 12 | 0.77 | Why? |
| Lymphocytic Choriomeningitis | 2 | 2018 | 43 | 0.72 | Why? |
| Liver Diseases | 6 | 2019 | 2698 | 0.70 | Why? |
| Lymphocytic choriomeningitis virus | 2 | 2018 | 98 | 0.69 | Why? |
| Adenosine Triphosphatases | 1 | 2017 | 78 | 0.69 | Why? |
| Cholangitis | 1 | 2017 | 81 | 0.63 | Why? |
| Lipid Metabolism | 1 | 2017 | 572 | 0.47 | Why? |
| Cholangiocarcinoma | 3 | 2019 | 186 | 0.45 | Why? |
| Liver Regeneration | 2 | 2019 | 38 | 0.39 | Why? |
| Cholangitis, Sclerosing | 3 | 2018 | 106 | 0.39 | Why? |
| Liver | 8 | 2019 | 4007 | 0.37 | Why? |
| Kupffer Cells | 2 | 2017 | 34 | 0.34 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.32 | Why? |
| Mice, Knockout | 4 | 2018 | 1815 | 0.29 | Why? |
| Bile Duct Neoplasms | 2 | 2019 | 172 | 0.29 | Why? |
| Hepatocytes | 2 | 2018 | 549 | 0.27 | Why? |
| Mice | 10 | 2019 | 21357 | 0.25 | Why? |
| Mesylates | 1 | 2021 | 33 | 0.23 | Why? |
| Cholesterol 7-alpha-Hydroxylase | 1 | 2019 | 3 | 0.20 | Why? |
| Disease Models, Animal | 5 | 2019 | 10998 | 0.20 | Why? |
| Amphiregulin | 1 | 2019 | 38 | 0.20 | Why? |
| Bile Canaliculi | 1 | 2018 | 1 | 0.20 | Why? |
| Transcription Factor RelB | 1 | 2018 | 9 | 0.20 | Why? |
| Aquaporin 2 | 1 | 2018 | 2 | 0.20 | Why? |
| Receptors, Lysosphingolipid | 1 | 2019 | 25 | 0.20 | Why? |
| Kidney Tubules, Collecting | 1 | 2018 | 4 | 0.20 | Why? |
| Sustained Virologic Response | 1 | 2021 | 378 | 0.19 | Why? |
| Esters | 1 | 2021 | 300 | 0.19 | Why? |
| Dermatitis | 1 | 2021 | 188 | 0.19 | Why? |
| Animals | 16 | 2019 | 78931 | 0.19 | Why? |
| Arenaviridae Infections | 1 | 2018 | 43 | 0.19 | Why? |
| Graft Rejection | 2 | 2021 | 1766 | 0.19 | Why? |
| Mice, Inbred C57BL | 6 | 2019 | 5542 | 0.18 | Why? |
| Bicarbonates | 1 | 2017 | 33 | 0.18 | Why? |
| Homeostasis | 2 | 2019 | 582 | 0.18 | Why? |
| Hypertension, Portal | 1 | 2018 | 73 | 0.17 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 252 | 0.17 | Why? |
| Epithelial Cells | 3 | 2018 | 3508 | 0.17 | Why? |
| Erythema | 1 | 2021 | 400 | 0.16 | Why? |
| Pharmacovigilance | 1 | 2021 | 501 | 0.16 | Why? |
| Isoxazoles | 1 | 2017 | 68 | 0.16 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.16 | Why? |
| Guanidines | 1 | 2021 | 499 | 0.16 | Why? |
| Cysts | 1 | 2017 | 94 | 0.15 | Why? |
| Transcriptional Activation | 1 | 2017 | 196 | 0.15 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.15 | Why? |
| Cell Proliferation | 3 | 2018 | 1973 | 0.15 | Why? |
| Signal Transduction | 5 | 2018 | 7207 | 0.15 | Why? |
| Radiation Dosage | 1 | 2020 | 585 | 0.15 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.14 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.14 | Why? |
| MAP Kinase Signaling System | 1 | 2017 | 360 | 0.14 | Why? |
| B-Lymphocytes | 2 | 2019 | 4418 | 0.13 | Why? |
| Informed Consent | 1 | 2021 | 890 | 0.13 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.13 | Why? |
| Water | 1 | 2018 | 765 | 0.13 | Why? |
| Cells, Cultured | 4 | 2018 | 5835 | 0.13 | Why? |
| Up-Regulation | 2 | 2021 | 2249 | 0.12 | Why? |
| Liver Transplantation | 2 | 2018 | 2864 | 0.11 | Why? |
| Pichia | 1 | 2011 | 42 | 0.11 | Why? |
| ATP-Binding Cassette Transporters | 1 | 2011 | 48 | 0.11 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.11 | Why? |
| Exocytosis | 1 | 2010 | 34 | 0.11 | Why? |
| Glutamic Acid | 1 | 2010 | 65 | 0.10 | Why? |
| Genetic Variation | 2 | 2017 | 3919 | 0.10 | Why? |
| Ammonia | 1 | 2010 | 61 | 0.10 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.09 | Why? |
| Germany | 2 | 2021 | 9196 | 0.09 | Why? |
| Astrocytes | 1 | 2010 | 298 | 0.09 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.09 | Why? |
| Virus Replication | 2 | 2021 | 14331 | 0.09 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.08 | Why? |
| Interferon Type I | 2 | 2018 | 2789 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Humans | 24 | 2021 | 930598 | 0.08 | Why? |
| Autoantibodies | 1 | 2018 | 2094 | 0.08 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.08 | Why? |
| Genetic Predisposition to Disease | 2 | 2017 | 4027 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.07 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Protein Transport | 2 | 2018 | 487 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Rats, Wistar | 2 | 2018 | 621 | 0.06 | Why? |
| Adult | 8 | 2021 | 244371 | 0.06 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.06 | Why? |
| Infant | 3 | 2018 | 30274 | 0.05 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.05 | Why? |
| Histamine Antagonists | 1 | 2021 | 203 | 0.05 | Why? |
| RNA-Directed DNA Polymerase | 1 | 2020 | 170 | 0.05 | Why? |
| Child | 2 | 2021 | 70012 | 0.05 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Dicarbethoxydihydrocollidine | 1 | 2018 | 1 | 0.05 | Why? |
| Lymphotoxin-beta | 1 | 2018 | 6 | 0.05 | Why? |
| Deubiquitinating Enzyme CYLD | 1 | 2018 | 9 | 0.05 | Why? |
| Lymphotoxin beta Receptor | 1 | 2018 | 8 | 0.05 | Why? |
| Lithocholic Acid | 1 | 2018 | 3 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2017 | 5837 | 0.05 | Why? |
| Cholic Acids | 1 | 2018 | 4 | 0.05 | Why? |
| Chenodeoxycholic Acid | 1 | 2018 | 9 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Carbon Tetrachloride | 1 | 2018 | 27 | 0.05 | Why? |
| Diabetes Insipidus, Nephrogenic | 1 | 2018 | 10 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.05 | Why? |
| Parenchymal Tissue | 1 | 2018 | 61 | 0.05 | Why? |
| RNA | 2 | 2021 | 1278 | 0.05 | Why? |
| Arenavirus | 1 | 2018 | 51 | 0.05 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
| Principal Component Analysis | 1 | 2021 | 689 | 0.05 | Why? |
| Butylated Hydroxyanisole | 1 | 2017 | 5 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Receptors, Tumor Necrosis Factor | 1 | 2017 | 40 | 0.04 | Why? |
| Platelet Membrane Glycoproteins | 1 | 2017 | 42 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2018 | 347 | 0.04 | Why? |
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2018 | 156 | 0.04 | Why? |
| Microfilament Proteins | 1 | 2017 | 45 | 0.04 | Why? |
| Female | 8 | 2021 | 380317 | 0.04 | Why? |
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2017 | 72 | 0.04 | Why? |
| Epoprostenol | 1 | 2017 | 41 | 0.04 | Why? |
| Rats | 2 | 2018 | 2764 | 0.04 | Why? |
| Optical Imaging | 1 | 2018 | 197 | 0.04 | Why? |
| ErbB Receptors | 1 | 2019 | 320 | 0.04 | Why? |
| Disclosure | 1 | 2021 | 423 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Cell Nucleus | 1 | 2018 | 399 | 0.04 | Why? |
| Cell Transformation, Neoplastic | 1 | 2017 | 191 | 0.04 | Why? |
| Steroids | 1 | 2021 | 904 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2017 | 264 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| Hepatectomy | 1 | 2018 | 276 | 0.04 | Why? |
| Carcinogenesis | 1 | 2017 | 236 | 0.04 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.04 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.03 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.03 | Why? |
| RNA, Messenger | 2 | 2018 | 5131 | 0.03 | Why? |
| Cell Adhesion Molecules | 1 | 2017 | 472 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.03 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Platelet Activation | 1 | 2017 | 660 | 0.03 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.03 | Why? |
| Spleen | 1 | 2017 | 877 | 0.03 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Egtazic Acid | 1 | 2010 | 1 | 0.03 | Why? |
| Vesicle-Associated Membrane Protein 2 | 1 | 2010 | 3 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| Pyridinium Compounds | 1 | 2010 | 19 | 0.03 | Why? |
| Prostaglandins | 1 | 2010 | 21 | 0.03 | Why? |
| Platelet Count | 1 | 2017 | 1381 | 0.03 | Why? |
| Cyclooxygenase Inhibitors | 1 | 2010 | 46 | 0.03 | Why? |
| Fluorometry | 1 | 2010 | 47 | 0.03 | Why? |
| Tissue Plasminogen Activator | 1 | 2017 | 778 | 0.03 | Why? |
| Indomethacin | 1 | 2010 | 47 | 0.03 | Why? |
| Male | 9 | 2021 | 367725 | 0.03 | Why? |
| Mutagenesis, Site-Directed | 1 | 2011 | 449 | 0.03 | Why? |
| Glial Fibrillary Acidic Protein | 1 | 2010 | 138 | 0.03 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.03 | Why? |
| Luminescent Proteins | 1 | 2010 | 142 | 0.03 | Why? |
| Chelating Agents | 1 | 2010 | 61 | 0.03 | Why? |
| Nitric Oxide | 1 | 2017 | 769 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2020 | 13720 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.02 | Why? |
| Cysteine Endopeptidases | 1 | 2018 | 1557 | 0.02 | Why? |
| Dendritic Cells | 1 | 2018 | 1330 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.02 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Saccharomyces cerevisiae | 1 | 2011 | 339 | 0.02 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.02 | Why? |
| Animals, Newborn | 1 | 2010 | 350 | 0.02 | Why? |
| Quaternary Ammonium Compounds | 1 | 2010 | 136 | 0.02 | Why? |
| DNA Mutational Analysis | 1 | 2011 | 581 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Transfection | 1 | 2010 | 864 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.02 | Why? |
| Phosphoproteins | 1 | 2017 | 4346 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| RNA, Small Interfering | 1 | 2010 | 817 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.02 | Why? |
| Calcium | 1 | 2010 | 708 | 0.02 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.02 | Why? |
| Base Sequence | 1 | 2011 | 3581 | 0.02 | Why? |
| Flow Cytometry | 1 | 2011 | 2393 | 0.01 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.01 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Colitis, Ulcerative | 1 | 2011 | 1037 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Bacterial Proteins | 1 | 2010 | 1318 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2010 | 3776 | 0.01 | Why? |
| Interleukin-6 | 1 | 2018 | 7522 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| HEK293 Cells | 1 | 2011 | 8394 | 0.01 | Why? |
| Thrombosis | 1 | 2017 | 7504 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Brain | 1 | 2010 | 5133 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |